All In Biotech

NDA 021323 · Abbvie

Lexapro

Escitalopram Oxalate · Oral

Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Aug 14, 2002

Approved uses

7

Original approval plus efficacy supplements

Registered trials

484

106 Phase 3, 29 recruiting

FAERS reports

127,231

84,617 serious, 10,109 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior s in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . Lexapro is not approved for use in pediatric patients less than 7 years of age [ s ee Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AN D BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and you ng adult patients taking antidepressants . Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Lexapro is not approved for use in pediatric patients less than 7 years of age (...

What it is approved for

From the label in effect Oct 1, 2023.

Lexapro is indicated for the treatment of: • major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. • generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older. Lexapro is a selective serotonin reuptake inhibitor (SSRI) indicated for the: treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older ( 1 ) treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years and older ( 1 )

Mechanism: The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • LEXAPRO · ESCITALOPRAM OXALATE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
  • LEXAPRO · ESCITALOPRAM OXALATE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
  • LEXAPRO · ESCITALOPRAM OXALATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Escitalopram Oxalate" as an intervention, any sponsor and status, largest first.

All 484 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea8,649
  • fatigue8,646
  • drug ineffective8,210
  • headache6,442
  • diarrhoea6,305
  • anxiety6,260
  • depression5,814
  • dizziness5,723
  • off label use5,573
  • pain5,306
  • fall5,050
  • vomiting4,742

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,788
20052,181
20062,103
20072,484
20082,407
20093,301
20104,363
20114,140
20124,641
20133,839
20144,290
20156,534
20168,096
20177,350
20188,674
20198,985
20208,696
20217,186
20227,544
20237,524
20247,739
20257,551
20265,814

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lexapro (Escitalopram Oxalate)

2024 spending

$17.6M

Beneficiaries

4,182

20,281 claims

Per beneficiary

$4,209

$14.04 per unit

View as table
YearSpending
2020$20,941,265
2021$20,061,718
2022$19,479,267
2023$18,746,937
2024$17,602,517

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 27 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.